Roche CEO frustrated by Genentech talks

In an interview with the Wall Street Journal, Roche CEO Severin Schwan reiterated his confidence that Roche will complete its acquisition of Genentech, but expressed frustration with the so-far fruitless negotiations. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.